Biofrontera (BFRI) Competitors $0.84 +0.01 (+0.64%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$0.83 -0.02 (-1.81%) As of 09/5/2025 06:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock BFRI vs. EPIX, XLO, ESLA, THAR, MURA, SCYX, JATT, RVPH, HYPD, and RNXTShould you be buying Biofrontera stock or one of its competitors? The main competitors of Biofrontera include ESSA Pharma (EPIX), Xilio Therapeutics (XLO), Estrella Immunopharma (ESLA), Tharimmune (THAR), Mural Oncology (MURA), SCYNEXIS (SCYX), JATT Acquisition (JATT), Reviva Pharmaceuticals (RVPH), Hyperion DeFi (HYPD), and RenovoRx (RNXT). These companies are all part of the "pharmaceutical products" industry. Biofrontera vs. Its Competitors ESSA Pharma Xilio Therapeutics Estrella Immunopharma Tharimmune Mural Oncology SCYNEXIS JATT Acquisition Reviva Pharmaceuticals Hyperion DeFi RenovoRx ESSA Pharma (NASDAQ:EPIX) and Biofrontera (NASDAQ:BFRI) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, risk, dividends, valuation, media sentiment and earnings. Which has more volatility & risk, EPIX or BFRI? ESSA Pharma has a beta of 1.6, meaning that its share price is 60% more volatile than the S&P 500. Comparatively, Biofrontera has a beta of 0.49, meaning that its share price is 51% less volatile than the S&P 500. Do insiders and institutionals have more ownership in EPIX or BFRI? 75.1% of ESSA Pharma shares are held by institutional investors. Comparatively, 10.1% of Biofrontera shares are held by institutional investors. 15.5% of ESSA Pharma shares are held by insiders. Comparatively, 4.8% of Biofrontera shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Do analysts recommend EPIX or BFRI? ESSA Pharma presently has a consensus price target of $2.00, suggesting a potential upside of 758.74%. Biofrontera has a consensus price target of $2.75, suggesting a potential upside of 225.71%. Given ESSA Pharma's higher probable upside, analysts plainly believe ESSA Pharma is more favorable than Biofrontera.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ESSA Pharma 0 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Biofrontera 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is EPIX or BFRI more profitable? ESSA Pharma has a net margin of 0.00% compared to Biofrontera's net margin of -42.34%. ESSA Pharma's return on equity of -21.71% beat Biofrontera's return on equity.Company Net Margins Return on Equity Return on Assets ESSA PharmaN/A -21.71% -21.22% Biofrontera -42.34%-1,104.09%-82.28% Which has better valuation and earnings, EPIX or BFRI? Biofrontera has higher revenue and earnings than ESSA Pharma. ESSA Pharma is trading at a lower price-to-earnings ratio than Biofrontera, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioESSA PharmaN/AN/A-$28.54M-$0.56-0.42Biofrontera$37.32M0.23-$17.76M-$2.26-0.37 Does the media favor EPIX or BFRI? In the previous week, Biofrontera had 1 more articles in the media than ESSA Pharma. MarketBeat recorded 1 mentions for Biofrontera and 0 mentions for ESSA Pharma. Biofrontera's average media sentiment score of 1.00 beat ESSA Pharma's score of 0.00 indicating that Biofrontera is being referred to more favorably in the news media. Company Overall Sentiment ESSA Pharma Neutral Biofrontera Positive SummaryESSA Pharma beats Biofrontera on 8 of the 15 factors compared between the two stocks. Get Biofrontera News Delivered to You Automatically Sign up to receive the latest news and ratings for BFRI and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BFRI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BFRI vs. The Competition Export to ExcelMetricBiofronteraMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$8.56M$3.17B$5.83B$9.92BDividend YieldN/A2.26%6.70%4.51%P/E Ratio-0.3721.2476.2926.13Price / Sales0.23433.21530.72175.33Price / CashN/A45.7236.9959.28Price / Book1.489.8711.486.09Net Income-$17.76M-$53.42M$3.29B$266.51M7 Day Performance-4.72%2.93%1.28%0.45%1 Month Performance-11.13%11.43%8.56%5.05%1 Year Performance-23.94%16.14%61.19%26.03% Biofrontera Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BFRIBiofrontera2.6973 of 5 stars$0.84+0.6%$2.75+225.7%-23.9%$8.56M$37.32M-0.3770Positive NewsShort Interest ↓EPIXESSA Pharma2.9973 of 5 stars$0.26-66.4%$2.00+660.2%-95.8%$37.08MN/A-0.4750Dividend AnnouncementHigh Trading VolumeXLOXilio Therapeutics2.1577 of 5 stars$0.700.0%$3.00+328.6%-13.9%$36.28M$6.34M-0.9270ESLAEstrella Immunopharma2.225 of 5 stars$0.97+0.1%$16.00+1,550.3%-4.5%$35.92MN/A-3.73N/AGap DownTHARTharimmune2.7971 of 5 stars$6.11-20.8%$17.00+178.2%+22.7%$35.74MN/A-1.002News CoverageShort Interest ↑Gap UpMURAMural Oncology3.35 of 5 stars$2.06flat$12.00+482.5%-34.3%$35.69MN/A-0.24119SCYXSCYNEXIS0.6947 of 5 stars$0.82-3.0%N/A-29.9%$35.43M$3.75M-2.0560News CoverageJATTJATT AcquisitionN/A$2.05+2.0%N/A-41.6%$35.36MN/A0.003High Trading VolumeRVPHReviva Pharmaceuticals2.745 of 5 stars$0.51-0.2%$5.20+910.3%-67.5%$35.06MN/A-0.795Gap UpHYPDHyperion DeFi0.1171 of 5 stars$6.98+14.4%$2.00-71.3%-84.5%$34.74M$60K-0.1240RNXTRenovoRx2.1444 of 5 stars$0.92+2.8%$7.25+684.8%+21.6%$32.92M$662K-2.436Negative NewsShort Interest ↑Gap Up Related Companies and Tools Related Companies EPIX Competitors XLO Competitors ESLA Competitors THAR Competitors MURA Competitors SCYX Competitors JATT Competitors RVPH Competitors HYPD Competitors RNXT Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BFRI) was last updated on 9/7/2025 by MarketBeat.com Staff From Our PartnersWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biofrontera Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Biofrontera With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
